Phyllis R. Yale's Insider Trades & SAST Disclosures
Phyllis R. Yale's most recent trade in DaVita Inc was a trade of 349 Common Stock done . Disclosure was reported to the exchange on March 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Phyllis R. Yale.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 349 | 12,853 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 3,562 | 34,677 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb Co. | R. Yale Phyllis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 618 | 30,796 | - | - | Deferred Share Units | |
| DaVita Inc | Yale Phyllis R. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2024 | 3,500 | 12,504 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2024 | 312 | 16,004 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 676 | 29,847 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 333 | 15,692 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 842 | 28,812 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 363 | 15,359 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 645 | 27,595 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 366 | 14,996 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 4,314 | 26,949 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb Co. | Yale Phyllis R. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 657 | 22,359 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 529 | 14,630 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2023 | 581 | 21,463 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 475 | 14,101 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 527 | 20,689 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 516 | 13,626 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 486 | 19,995 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 658 | 13,110 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 2,807 | 19,508 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 469 | 16,568 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 677 | 12,452 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 474 | 15,988 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 514 | 11,775 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 438 | 15,400 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 475 | 11,261 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 462 | 14,855 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 429 | 10,786 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 3,067 | 14,393 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2021 | 521 | 11,232 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 446 | 10,357 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 549 | 10,622 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2021 | 365 | 9,911 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 466 | 10,000 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.17 per share. | 22 Jun 2021 | 7,178 | 18,414 (0%) | 0% | 66.2 | 474,968 | Common Stock |
| DaVita Inc | Phyllis R. Yale | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 7,178 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Phyllis R. Yale | Director | Sale of securities on an exchange or to another person at price $ 124.33 per share. | 22 Jun 2021 | 5,048 | 9,546 (0%) | 0% | 124.3 | 627,601 | Common Stock |
| DaVita Inc | Phyllis R. Yale | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 4,579 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Phyllis R. Yale | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.44 per share. | 22 Jun 2021 | 4,579 | 14,125 (0%) | 0% | 78.4 | 359,177 | Common Stock |
| DaVita Inc | Phyllis R. Yale | Director | Sale or transfer of securities back to the company at price $ 124.36 per share. | 22 Jun 2021 | 3,820 | 14,594 (0%) | 0% | 124.4 | 475,055 | Common Stock |
| DaVita Inc | Phyllis R. Yale | Director | Sale or transfer of securities back to the company at price $ 124.36 per share. | 22 Jun 2021 | 2,889 | 11,236 (0%) | 0% | 124.4 | 359,276 | Common Stock |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 379 | 9,546 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 455 | 9,465 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 436 | 9,167 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 3,054 | 9,009 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2020 | 463 | 5,909 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2020 | 430 | 8,731 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 476 | 5,404 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2020 | 578 | 8,301 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 488 | 4,890 | - | - | Deferred Share Units | |
| DaVita Inc | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 599 | 7,723 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb Co. | Phyllis R. Yale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 515 | 4,369 | - | - | Deferred Share Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges